Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas

BACKGROUND. Src, EphA2, and platelet-derived growth factor receptors α and β are dysregulated in pancreatic ductal adenocarcinoma (PDAC). Dasatinib is an oral multitarget tyrosine kinase inhibitor that targets BCR-ABL, c-Src, c-KIT, platelet-derived growth factor receptor β, and EphA2. We conducted...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chee, Cheng Ean, Krishnamurthi, Smitha, Nock, Charles J., Meropol, Neal J., Gibbons, Joseph, Fu, PingFu, Bokar, Joseph, Teston, Lois, O'Brien, Timothy, Gudena, Vinay, Reese, Amy, Bergman, Mark, Saltzman, Joel, Wright, John J., Dowlati, Afshin, Brell, Joanna
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805150/
https://ncbi.nlm.nih.gov/pubmed/24072218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0255
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados